IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
-14.72%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$9.59M
AUM Growth
+$9.59M
(-98%)
Cap. Flow
-$470M
Cap. Flow
% of AUM
-4,907.13%
Top 10 Holdings %
Top 10 Hldgs %
47.01%
Holding
85
New
15
Increased
1
Reduced
62
Closed
7
Top Buys
| 1 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
$620K |
| 2 |
Exelixis
EXEL
|
$350K |
| 3 |
Caribou Biosciences
CRBU
|
$255K |
| 4 |
Galapagos
GLPG
|
$123K |
| 5 |
Ironwood Pharmaceuticals
IRWD
|
$60K |
Top Sells
| 1 |
Dyne Therapeutics
DYN
|
$68.7M |
| 2 |
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
|
$61.1M |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
$42.8M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$38.7M |
| 5 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$20.4M |
Sector Composition
| 1 | Healthcare | 91.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
IDEAYA Biosciences
IDYA
$2.26B
| $109K | 1.14% |
1,501
-107,499
| -99% | -$7.81M |
|
|
GMDA
27
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $107K | 1.12% |
187
-106,813
| -100% | -$61.1M |
|
28
Amicus Therapeutics
FOLD
$2.42B
| $94.6K | 0.99% |
1,017
-93,583
| -99% | -$8.7M |
|
29
BioMarin Pharmaceuticals
BMRN
$11.3B
| $79.7K | 0.83% |
6,601
-73,055
| -92% | -$882K |
|
30
Zai Lab
ZLAB
$3.48B
| $79K | 0.82% |
2,736
-76,222
| -97% | -$2.2M |
|
31
Guardant Health
GH
$8.11B
| $74.5K | 0.78% |
3,005
-71,495
| -96% | -$1.77M |
|
32
HUTCHMED
HCM
$2.62B
| $68K | 0.71% |
859
-67,141
| -99% | -$5.32M |
|
|
SGEN
33
DELISTED
Seagen Inc. Common Stock
SGEN
| $65.6K | 0.68% |
11,607
-64,593
| -85% | -$365K |
|
|
ITCI
34
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $63.2K | 0.66% |
3,603
-47,353
| -93% | -$830K |
|
35
Rocket Pharmaceuticals
RCKT
$358M
| $63K | 0.66% |
868
-62,132
| -99% | -$4.51M |
|
36
Immunovant
IMVT
$2.91B
| $60K | 0.63% |
233
-59,767
| -100% | -$15.4M |
|
|
37
Ironwood Pharmaceuticals
IRWD
$201M
| $60K | 0.63% |
+692
| New | +$60K |
|
38
Genmab
GMAB
$16.7B
| $57.2K | 0.6% |
+1,857
| New | +$57.2K |
|
39
BioCryst Pharmaceuticals
BCRX
$1.74B
| $57K | 0.59% |
602
-56,398
| -99% | -$5.34M |
|
40
Biogen
BIIB
$20.5B
| $52K | 0.54% |
+10,606
| New | +$52K |
|
41
Alkermes
ALKS
$4.95B
| $51K | 0.53% |
+1,519
| New | +$51K |
|
42
Allogene Therapeutics
ALLO
$249M
| $50K | 0.52% |
570
-49,430
| -99% | -$4.34M |
|
|
AVDL
43
Avadel Pharmaceuticals
AVDL
$1.45B
| $50K | 0.52% |
122
-49,878
| -100% | -$20.4M |
|
44
Illumina
ILMN
$15.2B
| $48K | 0.5% |
9,098
-40,246
| -82% | -$212K |
|
45
Ionis Pharmaceuticals
IONS
$9.64B
| $46.1K | 0.48% |
1,703
-152,385
| -99% | -$4.12M |
|
46
Krystal Biotech
KRYS
$4.35B
| $45K | 0.47% |
2,955
-42,045
| -93% | -$640K |
|
47
Amgen
AMGN
$153B
| $40.7K | 0.43% |
9,915
-56,831
| -85% | -$234K |
|
48
Insmed
INSM
$30.3B
| $40.1K | 0.42% |
791
-39,309
| -98% | -$1.99M |
|
49
Alnylam Pharmaceuticals
ALNY
$58.6B
| $38K | 0.4% |
5,542
-32,458
| -85% | -$223K |
|
50
Denali Therapeutics
DNLI
$2.24B
| $38K | 0.4% |
1,118
-36,882
| -97% | -$1.25M |
|